Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,...
Reexamination Certificate
2006-08-29
2009-08-18
Huynh, Phuong (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
C424S145100, C530S350000, C530S389200, C530S412000, C530S413000
Reexamination Certificate
active
07575745
ABSTRACT:
A novel polypeptide ligand, p30, or LIGHT, for herpes virus entry mediator, HVEM, is provided. LIGHT is useful for modulating immune responses and in inhibiting infection and/or subsequent proliferation by herpesvirus. HVEM fusion proteins are also provided. Methods for treating subjects with lymphoid cell disorders, tumors, autoimmune diseases, inflammatory disorders or those having or suspected of having a herpesvirus infection, utilizing p30 and the fusion proteins of the invention, are also provided.
REFERENCES:
patent: 6140467 (2000-10-01), Ware
patent: 6479254 (2002-11-01), Ebner et al.
patent: 6495520 (2002-12-01), Ebner et al.
patent: 6635743 (2003-10-01), Ebner et al.
patent: 6852837 (2005-02-01), Busfield
patent: 6998108 (2006-02-01), Ware
patent: 7118742 (2006-10-01), Ware
patent: 897 114 (1999-02-01), None
patent: WO 96 22788 (1996-08-01), None
patent: WO 97/03687 (1997-02-01), None
patent: WO 97 04658 (1997-02-01), None
patent: WO 97/34911 (1997-09-01), None
patent: WO 97 34911 (1997-09-01), None
patent: WO 98 03648 (1998-01-01), None
patent: WO 98 17313 (1998-04-01), None
patent: WO 98 18824 (1998-05-01), None
patent: WO 98 25967 (1998-06-01), None
patent: WO 98 51346 (1998-11-01), None
patent: WO 99 02563 (1999-01-01), None
patent: WO 99 11662 (1999-03-01), None
patent: WO 99 35262 (1999-07-01), None
patent: WO 99 42584 (1999-08-01), None
patent: WO 00 10591 (2000-03-01), None
patent: WO 00 14230 (2000-03-01), None
patent: WO 00 21558 (2000-04-01), None
patent: WO 00 53223 (2000-09-01), None
Ikuta et al, Virus research 6(2): 101-8, 1986, abstract only.
Van Noort et al, International Review of Cytology 178: 127-206, 1998.
Tian et al, Immunology Today 20(4): 190-195, Apr. 1999.
Ballow et al, J Allergy Clin Immunol 118: 1209-15, 2006.
Mauri et al, Immunity 8: 21-30, Jan. 1998.
Voelker et al, JAMA 282(21): 1992-1994, 1999.
Abaza, J., et al., Effects of amino acid substitutions outside an antigenic site on protein binding to monoclonal antibodies of predetermined specificity obtained by peptide immunization: demonstration with region 94-100 (antigenic site 3) of myoglobin, Journal of Protein Chemistry, 11(5):433-444 (1992).
Anderson, K., et al., Effects of tumor necrosis factor-α treatment on mortality in murine cytomegalovirus-infected mice, Antiviral Research, 21:343-355 (1993).
Attwood, Teresa K., Genomics: The babel of bioinformatics, Science Magazine, 290 (5491):471-472, 2000.
Bodey, B., et al., Failure of cancer vaccines: the significant limitations of this approach to immunotherapy, Anticancer Research 20:2665-2676 (2000).
Britt, W.J., et al., Cytomegalovirus, Fields Virology, 3rd ed., 77:2493-2494 (1996).
Browning et al., Signaling through the lymphotoxin β receptor induces the death of some adenocarcinoma tumor lines, J. Exp. Med The Rockefeller Univ. Press vol. 183, pp. 867-878 (1996).
Burnham; Polymers for delivering peptides and proteins; Am J Hosp Pharm, vol. 51; Jan. 15, 1994; p. 210-229.
Ezzell, C., Cancer “vaccines”: an idea whose time has come?, The Journal of NIH Research, 7:46-49 (1995).
Francis et al.; PEGylation of cytokeines and other therapeutic proteins and peptides; the importance of biological optimization of coupling techniques; International Journal of Hematology, vol. 68;1998; p. 1-18.
Goldenberg et al, Clin Ther 21(1):75-87, Jan. 1999.
Harrop et al., Antibodies to TR2 (herpesvirus entry mediator), a new member of the TNF receptor superfamily, block T cell proliferation, expression of activation markers, production of cytokines, J. Immunology, 161(4):1786-1794 (1998).
Harrop J et al., HVEM-L, a novel ligand for HVEM/TR2, stimulates NF-KB dependent transcription and T cell proliferation, Journal of Interferon and Cytokine Research, 18(5):A-39 (1998).
Harrop, J.A. et al., Herpesvirus entry mediator ligand (HVEM-L), a novel ligand for (HVEM/TR2, stimulates proliferation of T cells and inhibits HT29 cell growth, Journal of Biological Chemistry, American Society of Biological Chemists, Baltimore, MD, U.S., 273(42):27548-27556 (1998).
Hsu et al., Lymphotoxin-γ a novel ligand for lymphotoxin-β Receptor,Journal of Interferon and Cytokine Research 18(5): A-40, abstract 2.04, May 1998.
Huang et al., Anti-idiotypic antibodies mimicking glycoprotein D of herpes simplex virus identify a cellular protein required for virus spread from cell to cell and virus-induced polykaryocytosis, Proceedings of the National Academy of Science USA, Mar. 1996, vol. 93, pp. 1836-1840.
Inada et al.; Biomedical and biotechnological applications of PEG-andPM-modified proteins; Trends in Biotechnology, vol. 13; Mar. 1995; p. 86-91.
Kuby, J., Immunology, W.H. Freeman and Company, NY, 2ndEd., 85-96 (1994).
Kwon et al., A newly identified member of the tumor necrosis factor receptor superfamily with a wide tissue distribution and involvement in lymphocyte activation, J. Biological Chemistry, 272(22):14272-14276 (1997).
Mauri, D.N. et al., Light, a new member of the TNF superfamily, and lymphotoxin alpha are ligands for herpesvirus entry mediator, Immunity, Cell Press, U.S., 8:21-30 (1998).
Mckay et al.; Both the lymphotoxin and tumor necrosis factor pathways are involved in experimental murine models of colitis; gastroenterology, vol. 115; 1998; p. 1464-1475.
Mestas et al, The babel of bioinformatics, Oct. 2000, Science 290 (5491):471-473.
Montgomery et al., Herpes simplex virus-1 entry into cells mediated by a novel member of the TNF/NGF receptor family, Cell, Nov. 1, 1996, vol. 87, pp. 427-436.
Mumtaz et al.; Conjugation of proteins and enzymes with dydrophilic polymers and their applications; Indian Journal of Biochemistry & Biophysics, vol. 28, Oct. & Dec. 1991; p. 346-351.
Ngo, The protein folding problem and tertiary structure prediction, 492-495.
Norberg, P. et al., Phylogenetic Analysis of clinical herpes simplex virus type 1 isolates identified three genetic groups and recombinant viruses, Journal of Virology, 78(19):10755-10764 (2004).
Puglielli et al.; Reversal of virus-induced systemic shock and respiratory failure by blockade of the lymphotoxin pathway; Nature Medicine, vol. 5, No. 12; Dec. 1999; p. 1370-1374.
Skolnick et al, from genes to protein structure and function; novel applications of computational approaches in the genomic era, Jan. 2000, Trends in Biotech. 18(1): 34-39.
Spitler, L.E., Cancer Vaccines: The interferon analogy, Cancer Biotherapy, 10(1):1-3 (1995).
Stryer et al., Biochemistry, 3rded., W H Freeman Company, NY, pp. 31:33 (1998).
Tian et al, Immunology Today 20(4):190-195, Apr. 1999.
Van Noort et al., Cell biology of autoimmune diseases, International Review of Cytology, 178:127-205 (1998).
Voelker, R., Poor nations ravaged by AIDS need the right resources now, JAMA, 282 (21):1992-1994 (1999).
Whitley, R.J., Herpes Simplex Viruses, Fields Virology, 3rded., 73:2297-2303 (1996).
Zhai, Y. et al., Light, A novel ligand for lymphotoxin β Receptor and TR2/HVEM induces apoptosis and suppresses in vivo tumor formation via gene transfer, Journal of Clinical Investigation, New York, NY, U.S., 102(6):1142-1151 (1998).
Huynh Phuong
La Jolla Institute for Allergy and Immunology
Pillsbury Winthrop Shaw & Pittman LLP
LandOfFree
Ligand for herpes simplex virus entry mediator and methods... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Ligand for herpes simplex virus entry mediator and methods..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Ligand for herpes simplex virus entry mediator and methods... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4089921